Avandamet

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Ladda ner Bipacksedel (PIL)
08-06-2016
Ladda ner Produktens egenskaper (SPC)
08-06-2016

Aktiva substanser:

rosiglitazone, metformin hydrochloride

Tillgänglig från:

SmithKline Beecham Plc

ATC-kod:

A10BD03

INN (International namn):

rosiglitazone, metformin

Terapeutisk grupp:

Drugs used in diabetes

Terapiområde:

Diabetes Mellitus, Type 2

Terapeutiska indikationer:

AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

Produktsammanfattning:

Revision: 16

Bemyndigande status:

Withdrawn

Tillstånd datum:

2003-10-20

Bipacksedel

                                Medicinal product no longer authorised
105
B. PACKAGE LEAFLET
Medicinal product no longer authorised
106
PACKAGE LEAFLET: INFORMATION FOR THE USER
AVANDAMET 1 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/1000 MG FILM-COATED TABLETS
AVANDAMET 4 MG/1000 MG FILM-COATED TABLETS
rosiglitazone/metformin HCl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
-
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
-
IF ANY OF THE SIDE EFFECTS GETS SERIOUS, OR IF YOU NOTICE ANY SIDE
EFFECTS NOT LISTED IN THIS
LEAFLET, TELL YOUR DOCTOR OR PHARMACIST.
IN THIS LEAFLET
:
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
2.
BEFORE YOU TAKE AVANDAMET
3.
HOW TO TAKE AVANDAMET
4.
POSSIBLE SIDE EFFECTS
5
HOW TO STORE AVANDAMET
6.
FURTHER INFORMATION
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
AVANDAMET TABLETS ARE A COMBINATION OF TWO DIFFERENT MEDICINES
called
_rosiglitazone_
and
_metformin. _
These two medicines are used to treat
TYPE 2 DIABETES.
People with type 2 diabetes either don’t make enough insulin (a
hormone that controls blood sugar
levels), or don’t respond normally to the insulin their body makes.
Rosiglitazone and metformin work
together so your body makes better use of the insulin it produces, and
this helps reduce your blood
sugar to a normal level. Avandamet can be used alone or with a
sulphonylurea, another medicine for
diabetes.
2.
BEFORE YOU TAKE AVANDAMET
To help manage your diabetes, it is important that you follow any diet
and lifestyle advice from your
doctor as well as taking Avandamet.
DON’T TAKE AVANDAMET:
•
IF YOU ARE ALLERGIC
(
_hypersensitive_
) to rosiglitazone or metformin or any of the other
ingredients of Avandamet (
_listed in Section 6)_
•
IF YOU HAVE HAD A HEART ATTACK OR SEVERE ANGINA,
that’s being treated in hospital
•

                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
AVANDAMET 1 mg/500 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 1 mg of rosiglitazone (as rosiglitazone maleate)
and 500 mg of metformin
hydrochloride (corresponding to metformin free base 390 mg).
Excipients:
Each tablet contains lactose (approximately 6 mg).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Yellow film-coated tablets marked "gsk" on one side and "1/500" on the
other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
AVANDAMET is indicated in the treatment of type 2 diabetes mellitus
patients, particularly
overweight patients:
-
who are unable to achieve sufficient glycaemic control at their
maximally tolerated dose of oral
metformin alone.
-
in triple oral therapy with sulphonylurea in patients with
insufficient glycaemic control despite
dual oral therapy with their maximally tolerated dose of metformin and
a sulphonylurea (see
section 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The usual starting dose of AVANDAMET is 4 mg/day rosiglitazone plus
2000 mg/day metformin
hydrochloride.
Rosiglitazone can be increased to 8 mg/day after 8 weeks if greater
glycaemic control is required. The
maximum recommended daily dose of AVANDAMET is 8 mg rosiglitazone plus
2000 mg metformin
hydrochloride.
The total daily dose of AVANDAMET should be given in two divided
doses.
Dose titration with rosiglitazone (added to the optimal dose of
metformin) may be considered before
the patient is switched to AVANDAMET.
When clinically appropriate, direct change from metformin monotherapy
to AVANDAMET may be
considered.
Taking AVANDAMET with or just after food may reduce gastrointestinal
symptoms associated with
metformin.
Triple oral therapy (rosiglitazone, metformin and sulphonylurea) (see
section 4.4)
Medicinal product no longer authorised
3
-
Patients on metformin and sulp
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 08-06-2016
Produktens egenskaper Produktens egenskaper bulgariska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 08-06-2016
Bipacksedel Bipacksedel spanska 08-06-2016
Produktens egenskaper Produktens egenskaper spanska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 08-06-2016
Bipacksedel Bipacksedel tjeckiska 08-06-2016
Produktens egenskaper Produktens egenskaper tjeckiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 08-06-2016
Bipacksedel Bipacksedel danska 08-06-2016
Produktens egenskaper Produktens egenskaper danska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 08-06-2016
Bipacksedel Bipacksedel tyska 08-06-2016
Produktens egenskaper Produktens egenskaper tyska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 08-06-2016
Bipacksedel Bipacksedel estniska 08-06-2016
Produktens egenskaper Produktens egenskaper estniska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 08-06-2016
Bipacksedel Bipacksedel grekiska 08-06-2016
Produktens egenskaper Produktens egenskaper grekiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 08-06-2016
Bipacksedel Bipacksedel franska 08-06-2016
Produktens egenskaper Produktens egenskaper franska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 08-06-2016
Bipacksedel Bipacksedel italienska 08-06-2016
Produktens egenskaper Produktens egenskaper italienska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 08-06-2016
Bipacksedel Bipacksedel lettiska 08-06-2016
Produktens egenskaper Produktens egenskaper lettiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 08-06-2016
Bipacksedel Bipacksedel litauiska 08-06-2016
Produktens egenskaper Produktens egenskaper litauiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 08-06-2016
Bipacksedel Bipacksedel ungerska 08-06-2016
Produktens egenskaper Produktens egenskaper ungerska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 08-06-2016
Bipacksedel Bipacksedel maltesiska 08-06-2016
Produktens egenskaper Produktens egenskaper maltesiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 08-06-2016
Bipacksedel Bipacksedel nederländska 08-06-2016
Produktens egenskaper Produktens egenskaper nederländska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 08-06-2016
Bipacksedel Bipacksedel polska 08-06-2016
Produktens egenskaper Produktens egenskaper polska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 08-06-2016
Bipacksedel Bipacksedel portugisiska 08-06-2016
Produktens egenskaper Produktens egenskaper portugisiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 08-06-2016
Bipacksedel Bipacksedel rumänska 08-06-2016
Produktens egenskaper Produktens egenskaper rumänska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 08-06-2016
Bipacksedel Bipacksedel slovakiska 08-06-2016
Produktens egenskaper Produktens egenskaper slovakiska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 08-06-2016
Bipacksedel Bipacksedel slovenska 08-06-2016
Produktens egenskaper Produktens egenskaper slovenska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 08-06-2016
Bipacksedel Bipacksedel finska 08-06-2016
Produktens egenskaper Produktens egenskaper finska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 08-06-2016
Bipacksedel Bipacksedel svenska 08-06-2016
Produktens egenskaper Produktens egenskaper svenska 08-06-2016
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 08-06-2016

Sök varningar relaterade till denna produkt

Visa dokumenthistorik